About ERS Genomics
ERS Genomics is a Healthcare company based in Dublin (Ireland) founded in 2014 by Emmanuelle Charpentier. Developer of genome editing technology by using CRISPR-Cas9. Its chief executive, as recorded, is John Milad. ERS Genomics offers products and services including CRISPR/Cas9 Licensing and Express License. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
ERS Genomics offers CRISPRCas9 Licensing, Express License while focusing on life sciences, focusing on genomic solutions, enabling technologies, technology platforms, and gene editing. Developer of genome editing technology by using CRISPR-Cas9. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
- Headquarters Dublin, Ireland
- Founders Emmanuelle Charpentier
- SectorsHealthcare
- Email••••••••
- Website ersgenomics.com
- Social LinkedIn X
- Investors
Products & Services of ERS Genomics
ERS Genomics offers a comprehensive portfolio of products and services, including CRISPR/Cas9 Licensing and Express License.
Provides global access to patents for gene editing innovations.
Simplifies access to CRISPR/Cas9 technology for startups and researchers.
Funding Insights of ERS Genomics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of ERS Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in ERS Genomics
ERS Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science solutions for healthcare and agriculture are delivered. | 1863 | bayer.com | Leverkusen, Germany |
Investor details for ERS Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ERS Genomics
12 people are tracked at ERS Genomics (9 in leadership, 2 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Emmanuelle Charpentier | Co-Founder | Leadership |
John Milad | CEO | Leadership |
John E. Milad | Chief Executive Officer | Leadership |
Ross Kelly Fca | VP Of Finance | Leadership |
Ralph Vogelsang | Senior Director of Business Development & Licensing | Leadership |
Jon K. | Senior Vice President Business Development | Leadership |
Jon Kratochvil | VP of Business Development & Licensing, North America | Leadership |
Paul Carter | Senior Director of Business Development & Licensing, North America | Leadership |
Michael Arciero | VP of IP & Commercial Development | Leadership |
Shaun Foy | Chairman & Co-Founder | Board & advisors |
Rodger Novak | Director & Co-Founder | Board & advisors |
Cillian McGorman | Commercial Operations Manager | Team |
Complete people profiles for ERS Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ERS Genomics
2 dated milestones of ERS Genomics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded ERS Genomics is founded.
- Funding First funding round.
Web traffic of ERS Genomics
The website of ERS Genomics (ersgenomics.com) receives about 3K visits a month.
- Monthly visits3K
▲ 13.9% vs previous month
Websites whose visitors overlap most with ERS Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| demeetra.com | 96% | 1.9K | #7,504,534 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ers Genomics
Complete news archive for ERS Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ERS Genomics
ERS Genomics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
ERS Genomics is headquartered in Dublin, Ireland.
John Milad is the CEO of ERS Genomics, as recorded in our data.
ERS Genomics offers CRISPRCas9 Licensing, Express License while focusing on life sciences, focusing on genomic solutions, enabling technologies, technology platforms, and gene editing. Developer of genome editing technology by using CRISPR-Cas9. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
ERS Genomics offers CRISPR/Cas9 Licensing and Express License.
ERS Genomics has 1 investor. Key investors include Bayer.